|
|
Vaccine Detail
|
Ad CMV I kappaB alpha |
| Vaccine Information |
- Vaccine Name: Ad CMV I kappaB alpha
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007194
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- TNF
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- GPT
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: Human cytomegalovirus infection can be used to induce the activation of NF-κB (DeMeritt et al., 2004).
- Description: Human cytomegalovirus infection can be used to induce the activation of NF-κB (Bowen et al., 2002; DeMeritt et al., 2004).
|
| Host Response |
|
|
| References |
Bowen et al., 2002: Bowen GP, Borgland SL, Lam M, Libermann TA, Wong NC, Muruve DA. Adenovirus vector-induced inflammation: capsid-dependent induction of the C-C chemokine RANTES requires NF-kappa B. Human gene therapy. 2002; 13(3); 367-379. [PubMed: 11860704].
DeMeritt et al., 2004: DeMeritt IB, Milford LE, Yurochko AD. Activation of the NF-kappaB pathway in human cytomegalovirus-infected cells is necessary for efficient transactivation of the major immediate-early promoter. Journal of virology. 2004; 78(9); 4498-4507. [PubMed: 15078930].
|
|
